Alamos Gold (AGI) is expected to report an improvement in its bottom line when it reports first-quarter 2025 results on April 30, 2025, after market close. The Zacks Consensus Estimate for Alamos Gold’s earnings has moved down 13.6% over the past 60 days to 19 cents per share. The figure indicates 46% growth from the year-ago quarter. Image Source: Zacks Investment ResearchAGI’s Earnings Surprise HistoryIn the trailing four quarters, Alamos Gold’s earnings matched the Zacks Consensus Estimate in one quarter ...

Core Viewpoint - Eli Lilly and Company is set to report its first-quarter earnings on May 1, with sales and earnings estimates at $12.62 billion and $3.52 per share respectively, while earnings estimates for 2025 have seen a decline from $23.53 to $22.43 per share over the past month [1][4]. Earnings Performance - The company has exceeded earnings expectations in three of the last four quarters, with an average earnings surprise of 8.47% [2][3]. - The last reported quarter showed an earnings surprise of 5.77% [2]. Earnings Estimates and Trends - Current earnings estimates for Q1, Q2, 2025, and 2026 are $3.52, $5.58, $22.43, and $31.15 respectively, with a notable decline in Q1 estimates from $4.64 to $3.52 over the past 30 days, reflecting a -22.30% revision [1][4]. Factors Influencing Upcoming Results - Top-line growth in Q1 is expected to be driven by demand for FDA-approved tirzepatide medicines, specifically diabetes drug Mounjaro and weight loss medicine Zepbound [5]. - Sales of Mounjaro and Zepbound were below expectations in the latter half of 2024, attributed to slower growth and unfavorable channel dynamics [5][6]. - The FDA's approval of Zepbound for moderate-to-severe obstructive sleep apnea is anticipated to contribute positively to sales [7]. Sales Estimates for Key Products - The Zacks Consensus Estimate for Mounjaro and Zepbound is $3.75 billion and $2.27 billion respectively, while internal estimates are $3.82 billion and $2.19 billion [8]. - Sales estimates for other drugs include Trulicity at $1.11 billion, Taltz at $663 million, Verzenio at $1.25 billion, Jardiance at $675 million, Olumiant at $228 million, and Emgality at $220 million [10]. Competitive Landscape - Lilly faces competition in the diabetes and obesity market, particularly from Novo Nordisk's Wegovy, with several companies developing GLP-1-based candidates that could threaten market dominance [22][23]. - Despite competition, Lilly is investing in obesity treatments and has new molecules in clinical development, including a promising oral GLP-1 agonist [24]. Stock Performance and Valuation - Lilly's stock has increased by 14.8% this year, outperforming the industry average of 1.5% [13]. - The stock is currently trading at a premium compared to the industry [16]. Investment Outlook - Despite challenges, Lilly is viewed as a strong investment due to its robust growth prospects and position as a leading drugmaker [25].

Core Viewpoint - Spotify Technology S.A. is expected to report strong earnings growth in Q1 2025, with earnings per share estimated at $2.32, reflecting a 121% year-over-year increase, and revenues projected at $4.5 billion, indicating a 13.3% growth compared to the previous year [1]. Earnings Estimates - The Zacks Consensus Estimate for Q1 earnings has seen two upward revisions and one downward revision in the past 30 days, with a 1.3% increase in the 2024 earnings estimate during the same period [2]. - The current earnings estimates for Q1, Q2, E1, and F2 are $2.32, $2.44, $10.55, and $13.56 respectively, showing a positive trend in revisions over the last 60 days [3]. Earnings Surprise History - Spotify has a notable earnings surprise history, surpassing the Zacks Consensus Estimate in two of the last four quarters, with an average positive surprise of 22% [4]. Earnings Prediction Model - The current Earnings ESP for Spotify is -8.61%, and it holds a Zacks Rank of 3 (Hold), indicating that the model does not predict a definitive earnings beat this time [5][6]. Subscriber Growth - The growth in subscribers and monthly active users (MAU) is expected to positively impact both revenue and earnings, with total MAUs estimated at 678.3 million (10.3% year-over-year growth), ad-supported MAUs at 426.4 million (10% growth), and premium subscribers at 265.41 million (11% growth) [8]. Stock Performance - Spotify's stock has experienced significant price increases, rallying 35% year-to-date, 58% over the past six months, and 109% in the past year, indicating a strong upward trend [9]. Investment Considerations - The company's strong performance metrics are attributed to price hikes, a loyal consumer base, and cost reductions, which have contributed to growth in both top and bottom lines [10]. - The expectation is for another robust quarterly performance driven by subscriber gains and increases in average revenue per user (ARPU), which will enhance the company's financial position [11]. Long-term Outlook - While current growth prospects for Spotify appear strong, there may be a potential correction in the stock price, suggesting that investors might consider waiting for a more opportune moment to invest [12]. - The long-term growth potential of the company remains strong, making it a stock to monitor for future investment opportunities [14].

Core Viewpoint - United Parcel Service (UPS) is expected to report a decline in both earnings and revenues for the first quarter of 2025, with earnings estimated at $1.42 per share, a 0.7% decrease from the previous year, and revenues projected at $21.06 billion, indicating a 3% decline from the same quarter last year [1][2]. Earnings and Revenue Estimates - The Zacks Consensus Estimate for UPS's earnings is $1.42 per share, reflecting a downward revision of seven cents over the past 60 days [1]. - Revenue estimates stand at $21.06 billion, which is a 3% decline compared to the year-ago quarter [2]. Earnings Surprise History - UPS has a history of earnings surprises, with an average surprise of 3.43% across the last four quarters [3]. Earnings Prediction Model - The current Earnings ESP for UPS is -4.08%, indicating a lower likelihood of an earnings beat this quarter [5][6]. - UPS holds a Zacks Rank of 4 (Sell), suggesting a bearish outlook [6]. Factors Influencing Q1 Results - Geopolitical uncertainties and high inflation are expected to negatively impact shipping volumes [7]. - Labor costs are anticipated to be high, while low fuel costs may provide some relief, with a projected 5.1% decrease in fuel expenses compared to Q1 2024 [8]. Stock Performance - UPS stock has declined by 32.9% over the past year, underperforming its industry, which saw a 29.7% decline, while the S&P 500 rose by 7% [10]. Valuation Metrics - UPS is trading at a forward sales multiple of 0.96, which is higher than its industry peers, indicating a stretched valuation [13]. Investment Thesis - A decline in shipping demand is expected, with average daily volumes projected to decrease by 8.5% in 2025 compared to 2024 [16]. - Recent easing signals in the U.S.-China trade tensions may provide some optimism, but concerns over dividend sustainability amid demand weakness remain [18]. Long-term Outlook - Despite near-term challenges, UPS's strong brand and network position it as a compelling long-term investment in the transportation sector [19].

Core Viewpoint - American Water Works (AWK) is expected to report its first-quarter 2025 results on April 30, with a prior earnings surprise of 7.96% in the last quarter [1] Group 1: Factors Impacting Q1 Performance - The first-quarter earnings are anticipated to benefit from infrastructure improvements due to capital investments and efficient cost management strategies [2] - In 2024, AWK completed 13 acquisitions, adding 69,500 new customers, which is expected to create fresh demand and boost quarterly revenues [2] - Nearly 100% of AWK's net income is generated from regulated operations, with new rates effective in the first quarter likely contributing positively to performance [3] Group 2: Q1 Expectations - The Zacks Consensus Estimate for earnings is $1.04 per share, reflecting a year-over-year increase of 9.5% [4] - The Zacks Consensus Estimate for revenues is $1.03 billion, indicating a 1.8% increase from the previous year [4] Group 3: Earnings Prediction - The current model does not predict an earnings beat for AWK, with an Earnings ESP of 0.00% [5] - AWK holds a Zacks Rank of 2 (Buy) [6] Group 4: Comparable Stocks - Middlesex Water Company (MSEX) is expected to report an earnings beat with an Earnings ESP of +9.09% and a Zacks Rank 1 [7] - Evergy (EVRG) is also likely to report an earnings beat with an Earnings ESP of +5.7% and a Zacks Rank 3 [8] - Essential Utilities (WTRG) is projected to have an earnings beat with an Earnings ESP of +2.08% and a Zacks Rank 3 [10]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Patria Investments, driven by higher revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - The earnings report is expected on May 2, 2025, with a consensus EPS estimate of $0.25, reflecting a +19.1% change year-over-year, and revenues projected at $81.42 million, up 34.4% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Patria Investments is lower than the consensus estimate, resulting in an Earnings ESP of -8%, indicating a bearish sentiment among analysts [10][11]. Historical Performance - In the last reported quarter, Patria Investments exceeded the expected EPS of $0.37 by delivering $0.58, resulting in a surprise of +56.76%. However, the company has only beaten consensus EPS estimates once in the last four quarters [12][13]. Conclusion - Given the current Earnings ESP and Zacks Rank of 4, Patria Investments does not appear to be a strong candidate for an earnings beat, suggesting that investors should consider additional factors before making investment decisions [16].

Company Overview - Amneal Pharmaceuticals (AMRX) is expected to report a year-over-year increase in earnings, with a projected EPS of $0.15, reflecting a change of +7.1% [3] - Revenues are anticipated to reach $714.78 million, representing an 8.4% increase from the previous year [3] Earnings Expectations - The consensus EPS estimate has been revised 3.23% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The company has an Earnings ESP of +2.27%, suggesting a likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Amneal's actual earnings were $0.12 per share, which was a -20% surprise compared to the expected $0.15 [12] - Over the last four quarters, Amneal has beaten consensus EPS estimates three times [13] Market Sentiment - The upcoming earnings report is set to be released on May 2, and the stock may move higher if the results exceed expectations [2] - The combination of a positive Earnings ESP and a Zacks Rank of 3 indicates a favorable outlook for Amneal's earnings performance [11]

Core Viewpoint - Atmus Filtration Technologies (ATMU) is anticipated to report a year-over-year decline in earnings and revenues for the quarter ended March 2025, which could significantly influence its stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for May 2, 2025, with a consensus estimate of $0.59 per share, reflecting a -1.7% change year-over-year. Revenues are projected to be $420.68 million, down 1.4% from the previous year [3][2]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 1.02%, indicating a collective reassessment by analysts regarding the company's earnings outlook [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Atmus Filtration is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -5.09%. This suggests a bearish sentiment among analysts regarding the company's earnings prospects [10][11]. Historical Performance - In the last reported quarter, Atmus Filtration exceeded the expected earnings of $0.53 per share by delivering $0.58, resulting in a surprise of +9.43%. The company has beaten consensus EPS estimates in the last four quarters [12][13]. Investment Considerations - Despite the potential for an earnings beat, Atmus Filtration does not currently appear to be a compelling candidate for such an outcome, especially given its Zacks Rank of 4, which complicates predictions of beating the consensus EPS estimate [16][11].

Core Viewpoint - The market anticipates CBOE Global (CBOE) will report a year-over-year increase in earnings and revenues for the quarter ended March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - CBOE is expected to report quarterly earnings of $2.31 per share, reflecting a year-over-year increase of +7.4%, and revenues are projected to be $549.8 million, up 9.5% from the previous year [3]. - The consensus EPS estimate has been revised 6.23% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for CBOE is higher than the consensus estimate, resulting in an Earnings ESP of +2.15% [10][11]. - CBOE holds a Zacks Rank of 2 (Buy), suggesting a strong likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, CBOE was expected to post earnings of $2.13 per share but delivered $2.10, resulting in a surprise of -1.41% [12]. - Over the past four quarters, CBOE has surpassed consensus EPS estimates three times [13]. Industry Comparison - IntercontinentalExchange (ICE), a peer in the Zacks Securities and Exchanges industry, is expected to report earnings of $1.70 per share for the same quarter, indicating a year-over-year change of +14.9% and revenues of $2.45 billion, up 7.1% [17]. - ICE's consensus EPS estimate has been revised 3% higher in the last 30 days, with an Earnings ESP of 0.51% and a Zacks Rank of 2, suggesting a likely earnings beat [18].

Core Viewpoint - BrightSpring Health Services, Inc. (BTSG) is expected to report a year-over-year increase in earnings and revenues for the quarter ended March 2025, with a consensus EPS estimate of $0.14, reflecting a +16.7% change, and revenues projected at $2.73 billion, up 5.9% from the previous year [1][3]. Earnings Expectations - The stock price may increase if the actual earnings exceed expectations in the upcoming report scheduled for May 2, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 1.73% lower over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +106.62% for BrightSpring, suggesting analysts have become more optimistic about the company's earnings prospects [11]. - The company currently holds a Zacks Rank of 3, indicating a hold position, which suggests a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, BrightSpring exceeded the expected EPS of $0.19 by delivering $0.22, resulting in a surprise of +15.79%. Over the last four quarters, the company has beaten consensus EPS estimates twice [13]. Industry Comparison - Another player in the Zacks Medical Services industry, Organon (OGN), is expected to report earnings of $0.92 per share, reflecting a year-over-year decline of -24.6%, with revenues projected at $1.54 billion, down 4.9% [17]. - Organon's consensus EPS estimate has been revised down by 1.7% over the last 30 days, and it currently has a negative Earnings ESP of -1.91%, making it difficult to predict a beat on the consensus EPS estimate [18].